Meeting
2023 ASCO Genitourinary Cancers Symposium
Patient perceptions of benefits and risks of adjuvant therapy in renal cell carcinoma.
Authors
Dena Battle
KCCure, Alexandria, VA
Dena Battle , Pavlos Msaouel , Sumanta Monty Pal , Ulka N. Vaishampayan , Michael D. Staehler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 663)
DOI
10.1200/JCO.2023.41.6_suppl.663
Abstract #
663
Poster Bd #
G14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2022 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.
First Author: Bradley Alexander McGregor
Poster
2022 ASCO Genitourinary Cancers Symposium
Quantifying absolute benefit of adjuvant treatments in renal cell carcinoma: A systematic review and network-meta-analysis.
First Author: Qurat Ul Ain Riaz Sipra
Poster
2021 Genitourinary Cancers Symposium
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
First Author: Elizabeth R. Plimack